A Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study in 60 to 80-Year-Old Adults to Assess the Safety and Immunogenicity of BARS13
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs Respiratory syncytial virus vaccine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Advaccine (Suzhou) Biopharmaceuticals
- 20 Sep 2024 Status changed from active, no longer recruiting to completed.
- 01 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2022 Planned number of patients changed from 120 to 125.